24 Apr 2017 Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
24 Apr 2017 XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
24 Apr 2017 Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection
24 Apr 2017 Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
24 Apr 2017 Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications
22 Apr 2017 Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
22 Apr 2017 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
22 Apr 2017 Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
21 Apr 2017 Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
20 Apr 2017 Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
19 Apr 2017 Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
19 Apr 2017 Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
18 Apr 2017 XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
18 Apr 2017 FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
18 Apr 2017 FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
17 Apr 2017 OncoMed's Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
17 Apr 2017 Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
12 Apr 2017 argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients
11 Apr 2017 Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
11 Apr 2017 Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
10 Apr 2017 Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
10 Apr 2017 OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
10 Apr 2017 OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint
10 Apr 2017 Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
07 Apr 2017 Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing